TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter6n01:6nDrug6nDefinitions,6nStandards,6nand6nInformation6nSources6nWillihn
ganz:6nClayton’s6nBasic6nPharmacology6nfor6nNurses,6n19th6nEdition
MULTIPLE6nCHOIC
E
1. Which6nname6nidentifies6na6ndrug6nlisted6nby6nthe6nUS6nFoo
d6nand6nDrug6nAdministration6n(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:6n C
The6nofficial6nname6nis6nthe6 n name6nunder6nwhich6na6ndrug6nis6
nlisted6nby6nthe6nFDA.6nThe6nbrand6nname,6nor6ntrademark,6nis6nt
he6nname6ngiven6nto6na6ndrug6nby6nits6nmanufacturer.6nThe6nnon
proprietary,6nor6ngeneric,6nname6nis6nprovided6nby6nthe6nUnited
6nStates6nAdopted6nNames6nCouncil.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n9
OBJ:6n1NAT:6nNCLEX6nClient6nNeeds6nCategory:6nSafe,6nEffective
6nCare6nEnvironment6nTOP:6 n Nursing6nProcess6nStep:6nAssessment
CON:6
nPatient6nEducation
2. Which6nsource6ncontains6ninformation6nspecific6nto6nnutritional6nsupplements?
a. USP6nDictionary6nof6nUSAN6n &6nInternational6nDrug6nNames
b. Natural6nMedicines6nComprehensive6nDatabase
c. United6nStates6nPharmacopoeia/National6nFormulary6n(USP6nNF)
d. Drug6nInteraction6nFacts
ANS:6n C
United6nStates6nPharmacopoeia/National6nFormulary6ncontains6ninformation6nspecific6nto6nnutriti
onal6nsupplements.6nUSP6nDictionary6nof6nUSAN6n&6nInternational6nDrug6nNames6nis6na6ncompilat
ion6nof6ndrug6nnames,6npronunciation6nguide,6nand6npossible6nfuture6nFDA6napproved6ndrugs;6nit6nd
oes6nnot6ninclude6nnutritional6nsupplements.6nNatural6nMedicines6nComprehensive6nDatabase6nc
ontains
evidence-
based6ninformation6non6nherbal6nmedicines6nand6nherbal6ncombination6nproducts;6nit6ndoes6nnot6nincl
ude6ninformation6nspecific6nto6nnutritional6nsupplements.6nDrug6nInteraction6nFacts6ncontains6nco
mprehensive6ninformation6non6ndrug6ninteraction6nfacts;6nit6ndoes6nnot6ninclude6nnutritional6nsupp
lements.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n4
OBJ:6n36nNAT:6 n NCLEX6nClient6nNeeds6nCategory:6nPhysiological6
nIntegrity
TOP:6 n Nursing6nProcess6nStep:6nAssessment CON:6 n Nutrition6n|6nPatient6nEducation
3. Which6ndrug6nreference6ncontains6ndrug6nmonographs6nthat6ndescribe6nall6ndrugs6nin6na6ntherapeutic6nclass?
a. Drug6nFacts6nand6nComparisons
,Test6nBank6nFor6nClayton’s6nBasic6nPharmacology6nfor6nNurses6n19th6 3
nEdition
b. Drug6nInteraction6nFacts
c. Handbook6non6nInjectable6nDrugs
d. Martindale—The6nComplete6nDrug6nReference
ANS:6 n A
Drug6nFacts6nand6nComparisons6ncontains6ndrug6nmonographs6nthat6ndescribe6nall6ndrug
s6nin6na6ntherapeutic6nclass.6nMonographs6nare6nformatted6nas6ntables6nto6nallow6ncompariso
n6nof6nsimilar6pn roducts,6nbrand6nnames,6nmanufacturers,6ncost6nindices,6nand6navailable6nd
osage6nforms6nOnline6nversion6nis6navailable.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n46nTable6n1.2
OBJ:6n6n6 n 3 NAT:6 n NCLEX6nClient6nNeeds6nCategory:6nPhysiological6nIntegrity
TOP:6 n Nursing6nProcess6nStep:6nAssessment CON:6 n Safety6n|6nPatient6nEducation6n|6nClinical6nJudgment
4. Which6ndrug6nreference6ncontains6nmonographs6nabout6n virtually6nevery6nsingle-
entity6ndrug6navailable6nin6nthe6nUnited6nStates6nand6ndescribes6ntherapeutic6nuses6nof6ndrugs,6nincl
uding6napproved6nand6nunapproved6nuses?
a. Martindale:6nThe6nComplete6nDrug6nReference
b. AHFS6nDrug6nInformation
c. Drug6nReference
d. Drug6nFacts6nand6nComparisons
ANS:6 n B
AHFS6nDrug6nInformation6ncontains6nmonographs6nabout6nvirtually6nevery6nsingle-
entity6ndrug6navailable6nin6nthe6nUnited6nStates6nand6ndescribes6ntherapeutic6nuses6nof6ndrugs,6ninclu
ding6napproved6nand6nunapproved6nuses.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n46nTable6n1.2
OBJ:6n6n6 n 3 NAT:6 n NCLEX6nClient6nNeeds6nCategory:6nPhysiological6nIntegrity
TOP:6 n Nursing6nProcess6nStep:6nPlanning CON:6 n Safety6n|6nPatient6nEducation6n|6nClinical6nJudgment
5. Which6nonline6ndrug6nreference6nmakes6navailable6nto6nhealthcare6nproviders6nand6nthe6npubli
c6na6nstandard,6ncomprehensive,6nup-to-
date6nlook6nup6nand6ndownloadable6nresource6nabout6nmedicines?
a. American6nDrug6nIndex
b. American6nHospital6nFormulary
c. DailyMed
d. Drug6nReference
ANS:6n C
DailyMed6nmakes6navailable6nto6nhealthcare6nproviders6nand6nthe6npublic6na6nstandard,6ncomprehe
nsive,6nup-to-
date6nlook6nup6nand6ndownloadable6nresource6nabout6nmedicines.6nThe6nAmerican6nDrug6nIndex6ni
s6nnot6nappropriate6nfor6npatient6nuse.6nThe6nAmerican6nHospital6nFormulary6nis6nnot6nappropriate
6nfor6npatient6n use.6nThe6ndrug6nreference6n is6nnot6nappropriate6nfor6npatient6n use.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n36n|6np.6n4
OBJ:6n36nNAT:6 n NCLEX6nClient6nNeeds6nCategory:6nPhysiological6
nIntegrity
TOP:6 n Nursing6nProcess6nStep:6nImplementation
CON:6 n Safety6n|6nPatient6nEducation6n|6nClinical6nJudgment
6. Which6nlegislation6nauthorizes6nthe6nFDA6nto6ndetermine6nthe6nsafety6nof6na6ndrug6nbefore6nits6nmarketing?
a. Federal6nFood,6nDrug,6nand6nCosmetic6nAct6n(1938)
b. Durham6nHumphrey6nAmendment6n(1952)
, Test6nBank6nFor6nClayton’s6nBasic6nPharmacology6nfor6nNurses6n19th6 4
nEdition
c. Controlled6nSubstances6nAct6n(1970)
d. Kefauver6nHarris6nDrug6nAmendment6n(1962)
ANS:6 n A
The6nFederal6nFood,6nDrug,6nand6nCosmetic6nAct6nof6n19386nauthorized6nthe6nFDA6nto6ndetermine
6nthe6nsafety6nof6nall6ndrugs6nbefore6nmarketing.6nLater6namendments6nand6nacts6nhelped6ntighten6n
FDA6ncontrol6nand6nensure6ndrug6nsafety.6nThe6nDurham6nHumphrey6nAmendment6ndefines6nthe6n
kinds6nof6ndrugs6nthat6ncannot6nbe6nused6nsafely6nwithout6nmedical6nsupervision6nand6nrestricts6nth
eir6nsale6nto6nprescription6nby6na6nlicensed6npractitioner.6nThe6nControlled6nSubstances6nAct6naddre
sses6nonly6ncontrolled6nsubstances6nand6ntheir6ncategorization.6nThe6nKefauver6nHarris6nDrug6nAme
ndment6nensures6ndrug6nefficacy6nand6ngreater6ndrug6nsafety.6nDrug6nmanufacturers6nare6nrequired6n
to6nprove6nto6nthe6nFDA6nthe6neffectiveness6nof6ntheir6nproducts6nbefore6nmarketing6nthem.
DIF: Cognitive6nLevel:6nKnowledge REF:6np.6n56nTable6nl.3
OBJ:6 n 5
NAT:6nNCLEX6nClient6nNeeds6nCategory:6nPhysiological6nInte
grity6nTOP:6 n Nursing6nProcess6nStep:6nAssessment
CON:6 n Safety6n|6nPatient6nEducation6n|6nEvidence6n|6nHealth6nCare6nLaw
7. Which6nclassification6ndoes6nmeperidine6n(Demerol)6nfall6nunder?
a. I
b. II
c. III
d. IV
ANS:6 n B
Meperidine6n(Demerol)6nis6na6nSchedule6nII6ndrug;6nit6nhas6na6nhigh6npotential6nfor6nabuse6nand6nm
ay6nlead6nto6sn evere6npsychological6nand6nphysical6ndependence.6nSchedule6nI6ndrugs6nhave6nhigh6np
otential6nfor6nabuse6an nd6nno6nrecognized6nmedical6nuse.6nSchedule6nIII6ndrugs6nhave6nsome6npotent
ial6nfor6nabuse.6nUse6nmay6nlead6nto6nlow6nto6nmoderate6nphysical6ndependence6nor6nhigh6npsychol
ogical6ndependence.6nSchedule6nIV6ndrugs6nhave6nlow6npotential6nfor6nabuse.6nUse6nmay6nlead6nto6n
limited6nphysical6nor6npsychological6ndependence.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n10
OBJ:6n26nNAT:6 n NCLEX6nClient6nNeeds6nCategory:6nSafe,6nEffectiv
e6nCare6nEnvironment
TOP:6 n Nursing6nProcess6nStep:6nAssessment CON:6 n Patient6nEducation6n|6nAddiction6n|6nPain
8. Which6naction6nwould6nthe6nFDA6ntake6nto6nexpedite6ndrug6ndevelopment6nand6napproval6nfor6nan6no
utbreak6nof6nsmallpox?
a. List6nsmallpox6nas6na6nhealth6norphan6ndisease.
b. Omit6nthe6npreclinical6nresearch6nphase.
c. Extend6nthe6nclinical6nresearch6nphase.
d. Fast6ntrack6nthe6ninvestigational6ndrug.
ANS:6n D
Once6nthe6nInvestigational6nNew6nDrug6nApplication6nhas6nbeen6napproved,6nthe6ndrug6ncan6nrecei
ve6nhighest6npriority6nwithin6nthe6nagency,6nwhich6nis6ncalled6nfast6ntracking.6nA6nsmallpox6noutbr
eak6nwould6nbecome6na6npriority6nconcern6nin6nthe6nworld.6nOrphan6ndiseases6nare6nnot6nresearche
d6nin6na6npriority6nmanner.6nPreclinical6nresearch6nis6nnot6nomitted.6nExtending6nany6nphase6nof6nth
e6nresearch6nwould6nmean6na6nlonger6ntime6nto6ndevelop6na6nvaccine.6nThe6nFDA6nmust6nensure6nthat6n
all6nphases6nof6nthe6npreclinical6nand6nclinical6nresearch6nphase6nhave6nbeen6ncompleted6nin6na6nsafe6n
manner.
DIF: Cognitive6nLevel:6nKnowledge REF:6n6n6np.6n7 OBJ:6 n 5
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter6n01:6nDrug6nDefinitions,6nStandards,6nand6nInformation6nSources6nWillihn
ganz:6nClayton’s6nBasic6nPharmacology6nfor6nNurses,6n19th6nEdition
MULTIPLE6nCHOIC
E
1. Which6nname6nidentifies6na6ndrug6nlisted6nby6nthe6nUS6nFoo
d6nand6nDrug6nAdministration6n(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:6n C
The6nofficial6nname6nis6nthe6 n name6nunder6nwhich6na6ndrug6nis6
nlisted6nby6nthe6nFDA.6nThe6nbrand6nname,6nor6ntrademark,6nis6nt
he6nname6ngiven6nto6na6ndrug6nby6nits6nmanufacturer.6nThe6nnon
proprietary,6nor6ngeneric,6nname6nis6nprovided6nby6nthe6nUnited
6nStates6nAdopted6nNames6nCouncil.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n9
OBJ:6n1NAT:6nNCLEX6nClient6nNeeds6nCategory:6nSafe,6nEffective
6nCare6nEnvironment6nTOP:6 n Nursing6nProcess6nStep:6nAssessment
CON:6
nPatient6nEducation
2. Which6nsource6ncontains6ninformation6nspecific6nto6nnutritional6nsupplements?
a. USP6nDictionary6nof6nUSAN6n &6nInternational6nDrug6nNames
b. Natural6nMedicines6nComprehensive6nDatabase
c. United6nStates6nPharmacopoeia/National6nFormulary6n(USP6nNF)
d. Drug6nInteraction6nFacts
ANS:6n C
United6nStates6nPharmacopoeia/National6nFormulary6ncontains6ninformation6nspecific6nto6nnutriti
onal6nsupplements.6nUSP6nDictionary6nof6nUSAN6n&6nInternational6nDrug6nNames6nis6na6ncompilat
ion6nof6ndrug6nnames,6npronunciation6nguide,6nand6npossible6nfuture6nFDA6napproved6ndrugs;6nit6nd
oes6nnot6ninclude6nnutritional6nsupplements.6nNatural6nMedicines6nComprehensive6nDatabase6nc
ontains
evidence-
based6ninformation6non6nherbal6nmedicines6nand6nherbal6ncombination6nproducts;6nit6ndoes6nnot6nincl
ude6ninformation6nspecific6nto6nnutritional6nsupplements.6nDrug6nInteraction6nFacts6ncontains6nco
mprehensive6ninformation6non6ndrug6ninteraction6nfacts;6nit6ndoes6nnot6ninclude6nnutritional6nsupp
lements.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n4
OBJ:6n36nNAT:6 n NCLEX6nClient6nNeeds6nCategory:6nPhysiological6
nIntegrity
TOP:6 n Nursing6nProcess6nStep:6nAssessment CON:6 n Nutrition6n|6nPatient6nEducation
3. Which6ndrug6nreference6ncontains6ndrug6nmonographs6nthat6ndescribe6nall6ndrugs6nin6na6ntherapeutic6nclass?
a. Drug6nFacts6nand6nComparisons
,Test6nBank6nFor6nClayton’s6nBasic6nPharmacology6nfor6nNurses6n19th6 3
nEdition
b. Drug6nInteraction6nFacts
c. Handbook6non6nInjectable6nDrugs
d. Martindale—The6nComplete6nDrug6nReference
ANS:6 n A
Drug6nFacts6nand6nComparisons6ncontains6ndrug6nmonographs6nthat6ndescribe6nall6ndrug
s6nin6na6ntherapeutic6nclass.6nMonographs6nare6nformatted6nas6ntables6nto6nallow6ncompariso
n6nof6nsimilar6pn roducts,6nbrand6nnames,6nmanufacturers,6ncost6nindices,6nand6navailable6nd
osage6nforms6nOnline6nversion6nis6navailable.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n46nTable6n1.2
OBJ:6n6n6 n 3 NAT:6 n NCLEX6nClient6nNeeds6nCategory:6nPhysiological6nIntegrity
TOP:6 n Nursing6nProcess6nStep:6nAssessment CON:6 n Safety6n|6nPatient6nEducation6n|6nClinical6nJudgment
4. Which6ndrug6nreference6ncontains6nmonographs6nabout6n virtually6nevery6nsingle-
entity6ndrug6navailable6nin6nthe6nUnited6nStates6nand6ndescribes6ntherapeutic6nuses6nof6ndrugs,6nincl
uding6napproved6nand6nunapproved6nuses?
a. Martindale:6nThe6nComplete6nDrug6nReference
b. AHFS6nDrug6nInformation
c. Drug6nReference
d. Drug6nFacts6nand6nComparisons
ANS:6 n B
AHFS6nDrug6nInformation6ncontains6nmonographs6nabout6nvirtually6nevery6nsingle-
entity6ndrug6navailable6nin6nthe6nUnited6nStates6nand6ndescribes6ntherapeutic6nuses6nof6ndrugs,6ninclu
ding6napproved6nand6nunapproved6nuses.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n46nTable6n1.2
OBJ:6n6n6 n 3 NAT:6 n NCLEX6nClient6nNeeds6nCategory:6nPhysiological6nIntegrity
TOP:6 n Nursing6nProcess6nStep:6nPlanning CON:6 n Safety6n|6nPatient6nEducation6n|6nClinical6nJudgment
5. Which6nonline6ndrug6nreference6nmakes6navailable6nto6nhealthcare6nproviders6nand6nthe6npubli
c6na6nstandard,6ncomprehensive,6nup-to-
date6nlook6nup6nand6ndownloadable6nresource6nabout6nmedicines?
a. American6nDrug6nIndex
b. American6nHospital6nFormulary
c. DailyMed
d. Drug6nReference
ANS:6n C
DailyMed6nmakes6navailable6nto6nhealthcare6nproviders6nand6nthe6npublic6na6nstandard,6ncomprehe
nsive,6nup-to-
date6nlook6nup6nand6ndownloadable6nresource6nabout6nmedicines.6nThe6nAmerican6nDrug6nIndex6ni
s6nnot6nappropriate6nfor6npatient6nuse.6nThe6nAmerican6nHospital6nFormulary6nis6nnot6nappropriate
6nfor6npatient6n use.6nThe6ndrug6nreference6n is6nnot6nappropriate6nfor6npatient6n use.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n36n|6np.6n4
OBJ:6n36nNAT:6 n NCLEX6nClient6nNeeds6nCategory:6nPhysiological6
nIntegrity
TOP:6 n Nursing6nProcess6nStep:6nImplementation
CON:6 n Safety6n|6nPatient6nEducation6n|6nClinical6nJudgment
6. Which6nlegislation6nauthorizes6nthe6nFDA6nto6ndetermine6nthe6nsafety6nof6na6ndrug6nbefore6nits6nmarketing?
a. Federal6nFood,6nDrug,6nand6nCosmetic6nAct6n(1938)
b. Durham6nHumphrey6nAmendment6n(1952)
, Test6nBank6nFor6nClayton’s6nBasic6nPharmacology6nfor6nNurses6n19th6 4
nEdition
c. Controlled6nSubstances6nAct6n(1970)
d. Kefauver6nHarris6nDrug6nAmendment6n(1962)
ANS:6 n A
The6nFederal6nFood,6nDrug,6nand6nCosmetic6nAct6nof6n19386nauthorized6nthe6nFDA6nto6ndetermine
6nthe6nsafety6nof6nall6ndrugs6nbefore6nmarketing.6nLater6namendments6nand6nacts6nhelped6ntighten6n
FDA6ncontrol6nand6nensure6ndrug6nsafety.6nThe6nDurham6nHumphrey6nAmendment6ndefines6nthe6n
kinds6nof6ndrugs6nthat6ncannot6nbe6nused6nsafely6nwithout6nmedical6nsupervision6nand6nrestricts6nth
eir6nsale6nto6nprescription6nby6na6nlicensed6npractitioner.6nThe6nControlled6nSubstances6nAct6naddre
sses6nonly6ncontrolled6nsubstances6nand6ntheir6ncategorization.6nThe6nKefauver6nHarris6nDrug6nAme
ndment6nensures6ndrug6nefficacy6nand6ngreater6ndrug6nsafety.6nDrug6nmanufacturers6nare6nrequired6n
to6nprove6nto6nthe6nFDA6nthe6neffectiveness6nof6ntheir6nproducts6nbefore6nmarketing6nthem.
DIF: Cognitive6nLevel:6nKnowledge REF:6np.6n56nTable6nl.3
OBJ:6 n 5
NAT:6nNCLEX6nClient6nNeeds6nCategory:6nPhysiological6nInte
grity6nTOP:6 n Nursing6nProcess6nStep:6nAssessment
CON:6 n Safety6n|6nPatient6nEducation6n|6nEvidence6n|6nHealth6nCare6nLaw
7. Which6nclassification6ndoes6nmeperidine6n(Demerol)6nfall6nunder?
a. I
b. II
c. III
d. IV
ANS:6 n B
Meperidine6n(Demerol)6nis6na6nSchedule6nII6ndrug;6nit6nhas6na6nhigh6npotential6nfor6nabuse6nand6nm
ay6nlead6nto6sn evere6npsychological6nand6nphysical6ndependence.6nSchedule6nI6ndrugs6nhave6nhigh6np
otential6nfor6nabuse6an nd6nno6nrecognized6nmedical6nuse.6nSchedule6nIII6ndrugs6nhave6nsome6npotent
ial6nfor6nabuse.6nUse6nmay6nlead6nto6nlow6nto6nmoderate6nphysical6ndependence6nor6nhigh6npsychol
ogical6ndependence.6nSchedule6nIV6ndrugs6nhave6nlow6npotential6nfor6nabuse.6nUse6nmay6nlead6nto6n
limited6nphysical6nor6npsychological6ndependence.
DIF: Cognitive6nLevel:6nKnowledge REF:6 n p.6n10
OBJ:6n26nNAT:6 n NCLEX6nClient6nNeeds6nCategory:6nSafe,6nEffectiv
e6nCare6nEnvironment
TOP:6 n Nursing6nProcess6nStep:6nAssessment CON:6 n Patient6nEducation6n|6nAddiction6n|6nPain
8. Which6naction6nwould6nthe6nFDA6ntake6nto6nexpedite6ndrug6ndevelopment6nand6napproval6nfor6nan6no
utbreak6nof6nsmallpox?
a. List6nsmallpox6nas6na6nhealth6norphan6ndisease.
b. Omit6nthe6npreclinical6nresearch6nphase.
c. Extend6nthe6nclinical6nresearch6nphase.
d. Fast6ntrack6nthe6ninvestigational6ndrug.
ANS:6n D
Once6nthe6nInvestigational6nNew6nDrug6nApplication6nhas6nbeen6napproved,6nthe6ndrug6ncan6nrecei
ve6nhighest6npriority6nwithin6nthe6nagency,6nwhich6nis6ncalled6nfast6ntracking.6nA6nsmallpox6noutbr
eak6nwould6nbecome6na6npriority6nconcern6nin6nthe6nworld.6nOrphan6ndiseases6nare6nnot6nresearche
d6nin6na6npriority6nmanner.6nPreclinical6nresearch6nis6nnot6nomitted.6nExtending6nany6nphase6nof6nth
e6nresearch6nwould6nmean6na6nlonger6ntime6nto6ndevelop6na6nvaccine.6nThe6nFDA6nmust6nensure6nthat6n
all6nphases6nof6nthe6npreclinical6nand6nclinical6nresearch6nphase6nhave6nbeen6ncompleted6nin6na6nsafe6n
manner.
DIF: Cognitive6nLevel:6nKnowledge REF:6n6n6np.6n7 OBJ:6 n 5
